<DOC>
	<DOCNO>NCT03021187</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial investigate efficacy safety oral semaglutide versus placebo subject Type 2 Diabetes Mellitus treat insulin . All subject continue pre-trial insulin therapy ( basal , basal-bolus premixed regimen include combination soluble insulin ) throughout trial . Subjects treat metformin addition insulin treatment must continue metformin treatment throughout entire trial .</brief_summary>
	<brief_title>Efficacy Safety Oral Semaglutide Versus Placebo Subjects With Type 2 Diabetes Mellitus Treated With Insulin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial . Male female , age equal 18 year time signing informed consent . For Japan : Male female , age equal 20 year time signing informed consent . Diagnosed type 2 diabetes mellitus 90 day prior day screen . HbA1c ( glycosylated haemoglobin ) 7.09.5 % ( 5380 mmol/mol ) ( inclusive ) . Stable treatment one follow insulin regimen ( minimum 10 IU/day ) 90 day prior day screen . Maximum 20 % change total daily dose acceptable : ( 1 ) Basal insulin alone ( 2 ) Basal bolus insulin combination ( 3 ) Premixed insulin include combination soluble insulin Female pregnant , breastfeed intend become pregnant childbearing potential use adequate contraceptive method ( adequate contraceptive measure require local regulation practice ) . For Greece : adequate contraceptive measure define combined hormonal contraception ( contain oestrogen progesterone ) , suppress ovulation ( oral , intravaginal , percutaneous ) , progesteroneonly hormonal contraception suppress ovulation ( oral , injectable , implantable ) , intrauterine device , hormonereleasing intrauterine system , bilateral tubal occlusion , partner vasectomy , sexual abstinence . For Japan : Adequate contraceptive measure abstinence ( sex ) , diaphragm , condom ( partner ) , intrauterine device , sponge , spermicide oral contraceptive . For Canada : adequate contraceptive measure define combined hormonal contraception ( contain oestrogen progesterone ) , suppress ovulation ( oral , intravaginal , percutaneous ) , progesteroneonly hormonal contraception suppress ovulation ( oral , injectable , implantable ) , intrauterine device , hormonereleasing intrauterine system , bilateral tubal occlusion , partner vasectomy , sexual abstinence Any disorder , investigator 's opinion might jeopardise subject 's safety compliance protocol . Family personal history Multiple Endocrine Neoplasia Type 2 ( MEN 2 ) Medullary Thyroid Carcinoma ( MTC ) . History pancreatitis ( acute chronic ) . History major surgical procedure involve stomach potentially affect absorption trial product ( e.g . subtotal total gastrectomy , sleeve gastrectomy , gastric bypass surgery ) . Any follow : myocardial infarction ( MI ) , stroke hospitalisation unstable angina transient ischaemic attack within past 180 day prior day screen randomisation . Classified New York Heart Association ( NYHA ) Class IV . Planned coronary , carotid peripheral artery revascularisation know day screen . Renal impairment define estimate Glomerular Filtration Rate ( eGFR ) less 60 mL/min/1.73 m^2 per Chronic Kidney Disease Epidemiology Collaboration formula ( CKDEPI ) . Treatment medication indication diabetes obesity state inclusion criterion period 90 day day screen . An exception shortterm change insulin treatment acute illness total 14 day less . Known hypoglycaemic unawareness accord Clarke 's questionnaire . Proliferative retinopathy maculopathy require acute treatment . Verified fundus photography dilate fundoscopy perform within 90 day prior randomisation . History presence malignant neoplasm within last 5 year ( except basal squamous cell skin cancer carcinoma situ ) . Subjects alanine aminotransferase ( ALT ) 2.5 x upper normal limit ( UNL ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>